The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) closed the day trading at $7.71 up 1.05% from the previous closing price of $7.63. In other words, the price has increased by $1.05 from its previous closing price. On the day, 2.3 million shares were traded. BCRX stock price reached its highest trading level at $7.7607 during the session, while it also had its lowest trading level at $7.52.
Ratios:
For a better understanding of BCRX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.11. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.87.
On October 01, 2025, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $8.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.Cantor Fitzgerald initiated its Overweight rating on April 29, 2025, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 22 ’25 when Barnes Alane P sold 21,773 shares for $7.65 per share. The transaction valued at 166,563 led to the insider holds 398,751 shares of the business.
Barnes Alane P bought 21,773 shares of BCRX for $166,563 on Dec 22 ’25. On Dec 15 ’25, another insider, Barnes Alane P, who serves as the Chief Legal Officer of the company, sold 21,210 shares for $7.65 each. As a result, the insider received 162,256 and left with 315,726 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1624798080 and an Enterprise Value of 2093524224. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.71. Its current Enterprise Value per Revenue stands at 3.49 whereas that against EBITDA is 26.029.
Stock Price History:
The Beta on a monthly basis for BCRX is 0.81, which has changed by 0.014627695 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $11.31, while it has fallen to a 52-week low of $6.00. The 50-Day Moving Average of the stock is 6.30%, while the 200-Day Moving Average is calculated to be -6.60%.
Shares Statistics:
Over the past 3-months, BCRX traded about 5.10M shares per day on average, while over the past 10 days, BCRX traded about 3687880 shares per day. A total of 210.52M shares are outstanding, with a floating share count of 193.68M. Insiders hold about 8.10% of the company’s shares, while institutions hold 95.16% stake in the company. Shares short for BCRX as of 1765756800 were 36006145 with a Short Ratio of 7.07, compared to 1763078400 on 36461313. Therefore, it implies a Short% of Shares Outstanding of 36006145 and a Short% of Float of 17.150000000000002.
Earnings Estimates
A detailed examination of Biocryst Pharmaceuticals Inc (BCRX) is currently in progress, with 3.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.12, with high estimates of $0.13 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.47 and $0.09 for the fiscal current year, implying an average EPS of $0.33. EPS for the following year is $0.28, with 4.0 analysts recommending between $0.6 and -$0.04.
Revenue Estimates
9 analysts predict $149.95M in revenue for. The current quarter. It ranges from a high estimate of $156.03M to a low estimate of $145.14M. As of. The current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $131.53MFor the next quarter, 9 analysts are estimating revenue of $153.83M. There is a high estimate of $160.58M for the next quarter, whereas the lowest estimate is $144.5M.
A total of 9 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $624.31M, while the lowest revenue estimate was $613.1M, resulting in an average revenue estimate of $617.95M. In the same quarter a year ago, actual revenue was $450.71MBased on 10 analysts’ estimates, the company’s revenue will be $655.78M in the next fiscal year. The high estimate is $676.48M and the low estimate is $608M.
